MedTrace Logo

Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

NCT04628806 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-05-14

No results posted yet for this study

Summary

This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.

Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.

Conditions

Interventions

DIAGNOSTIC_TEST

CTC isolation by HSP70

patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.

Sponsors & Collaborators

  • Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Sebastian Zschaeck, MD · Charité

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-17
Primary Completion
2022-02-28
Completion
2022-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04628806 on ClinicalTrials.gov